- Home
- UCL vs RLYB Comparison
UCL vs RLYB Comparison
Compare UCL & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- RLYB
- Stock Information
- Founded
- UCL 2014
- RLYB 2018
- Country
- UCL Hong Kong
- RLYB United States
- Employees
- UCL N/A
- RLYB N/A
- Industry
- UCL Telecommunications Equipment
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- RLYB Health Care
- Exchange
- UCL Nasdaq
- RLYB Nasdaq
- Market Cap
- UCL 70.6M
- RLYB 14.4M
- IPO Year
- UCL 2020
- RLYB 2021
- Fundamental
- Price
- UCL $1.92
- RLYB $0.41
- Analyst Decision
- UCL
- RLYB Hold
- Analyst Count
- UCL 0
- RLYB 3
- Target Price
- UCL N/A
- RLYB $15.00
- AVG Volume (30 Days)
- UCL 51.0K
- RLYB 8.1M
- Earning Date
- UCL 08-13-2025
- RLYB 08-07-2025
- Dividend Yield
- UCL N/A
- RLYB N/A
- EPS Growth
- UCL N/A
- RLYB N/A
- EPS
- UCL 0.09
- RLYB N/A
- Revenue
- UCL $92,256,000.00
- RLYB $848,000.00
- Revenue This Year
- UCL $6.09
- RLYB N/A
- Revenue Next Year
- UCL $7.01
- RLYB N/A
- P/E Ratio
- UCL $20.58
- RLYB N/A
- Revenue Growth
- UCL 7.65
- RLYB N/A
- 52 Week Low
- UCL $0.80
- RLYB $0.22
- 52 Week High
- UCL $3.30
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- UCL 58.25
- RLYB 55.26
- Support Level
- UCL $1.79
- RLYB $0.32
- Resistance Level
- UCL $1.96
- RLYB $0.61
- Average True Range (ATR)
- UCL 0.14
- RLYB 0.05
- MACD
- UCL -0.02
- RLYB 0.01
- Stochastic Oscillator
- UCL 33.97
- RLYB 34.82
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.